Type 2 Diabetes Injections

a long-acting or intermediate-acting insulin once or twice a day, and a separate rapid-acting or short-acting insulin before meals

Mounjaro 5mg Injection

Request Callback

₹ 12800 / Vial Get Latest Price

Strength5 mg
Packaging Size0.5 ml
Packaging TypeInjection
BrandMounjaro 5mg 0.5 ml
ManufacturerEli lilly and Company
Usage / Applicationused for type 2 diabetes to help lower blood sugar levels, and tirzepatide also causes weight loss.
Storage ConditionsStore Mounjaro 5mg Solution for Injection in a refrigerator at 2 DegreeC to 8 DegreeC. If needed, it can be kept at room temperature (up to 30 DegreeC) for up to 21 days.
Mounjaro (tirzepatide) 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL injection, is a prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). It is not known if Mounjaro can be used in people who have had pancreatitis.

Mounjaro 2.5mg Injection

Request Callback

₹ 8000 / Vial Get Latest Price

Strength2.5 mg
Packaging Size0.5 ml
Packaging TypeInjection
BrandMounjaro 2.5mg
ManufacturerEli lilly & co.
Usage / ApplicationAs advised be the doctor
Shelf life24 months
Mounjaro 2.5mg Solution for Injection is a medication that contains tirzepatide and is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dapasmart 10mg tablets

Request Callback

₹ 410 / Strip Get Latest Price

Strength10 mg
CompositionDapagliflozin
Pack Size10 tablets
BrandDapasmart
UsageType 2 Diabetes
Shelf Life24 months
storagekeep it in cold and dry places but avoid from direct sunlight
Dapagliflozin 10mg is a medication primarily used to treat type 2 diabetes and can also be used for heart failure. It works by increasing glucose excretion through urine, which helps control blood sugar levels.
X

Contact Us

Laveena Anurag Hotwani (CEO)
Medinova Pharma
Plot No.143 144, Housing Board Society
Jaripatka, Nagpur - 440014, Maharashtra, India

Get Directions
Send Email
Share: